title: The current state of prostate-specific antigen testing.
abstract: Since prostate-specific antigen (PSA) testing was approved in 1994, the incidence of metastasis and mortality from prostate cancer have significantly decreased. However, PSA screening for prostate cancer has limitations and few large randomized controlled trials have been conducted to determine the mortality benefit of PSA screening. Two studies that have been conducted are the Prostate, Lung, Colorectal, and Ovarian (PLCO) screening trial and the European Randomized Study of Screening for Prostate Cancer (ERSPC). These were the two main studies the US Preventive Services Task Force (USPSTF) used in its recommendation against prostate cancer screening in 2012. However, new evidence has demonstrated that the PLCO trial had significant limitations and the results of the ERSPC trial were more significant than previously thought. This article describes the strengths and weaknesses of the USPSTF's recommendation, along with current guidelines for prostate cancer screening.
authors: Ryan Lewis is the current PA fellow in the University of Texas Southwestern Medical Center's PA postgraduate urology training program in Dallas. Brad Hornberger is a faculty associate and program director of the PA postgraduate urology training program in the Department of Urology at the University of Texas Southwestern Medical Center. The authors have disclosed no potential conflicts of interest, financial or otherwise.
authors: Ryan
authors: R
authors: Lewis
authors: Brad
authors: B
authors: Hornberger
mesh_terms: D026683:Advisory Committees; D055088:Early Detection of Cancer; D006801:Humans; D015994:Incidence; D008297:Male; D008403:Mass Screening; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000175:diagnosis*; D016032:Randomized Controlled Trials as Topic
chemical_list: D017430:Prostate-Specific Antigen